S

Sage Therapeutics
D

SAGE

6.72000
USD
0.12
(1.82%)
مغلق
حجم التداول
26,893
الربح لكل سهم
-3
العائد الربحي
-
P/E
-1
حجم السوق
420,811,064
أصول ذات صلة
A
ACAD
-0.050
(-0.23%)
21.710 USD
ALNY
ALNY
3.30
(1.08%)
308.00 USD
C
CRSP
0.050
(0.12%)
41.360 USD
INCY
INCY
-1.490
(-2.15%)
67.750 USD
I
IONS
-0.020
(-0.06%)
35.570 USD
O
OPK
-0.01000
(-0.74%)
1.33500 USD
REGN
REGN
7.50
(1.44%)
529.39 USD
VRTX
VRTX
-4.36
(-0.95%)
455.70 USD
المزيد
الأخبار المقالات

العنوان: Sage Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; alsotargeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment ofpostpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.